BioCentury
ARTICLE | Clinical News

BDM-E regulatory update

September 20, 2010 7:00 AM UTC

FDA granted Orphan Drug designation to BioDiem's BDM-E to treat retinitis pigmentosa. The synthetic peptide is in preclinical testing for the indication. The company is seeking partners and funding to...